
## Supplementary Material

Supplementary Figure 1. Representative three-dimensional reconstructed LA images and boundary of LA and PV volume.

Supplementary Figure 2. Comparisons of the predictive value of AF recurrence between LA dimension and PV/LA%vol in the tertile groups according to the LA dimension in selected patients who underwent circumferential PV isolation alone.

Supplementary Table 1. Cox regression analysis for clinical recurrence after AFCA in selected patients who underwent PV isolation alone.


Supplementary Table 2. Associated SNPs in PITX2 with PV/LA%vol in two different cohorts.



Supplementary Figure 1. Representative three-dimensional reconstructed LA images and boundary of LA and PV volume.

Three-dimensional reconstructed LA images in the AP (A) and PA views (B). The boundary of the PV was divided from the PV ostia to the primary tributaries with equal horizontal extension bilaterally in the AP (C) and PA views (D).

AP, anteroposterior; LA, left atrium or left atrial; PA, posteroanterior; PV, pulmonary vein.



Supplementary Figure 2. Comparisons of the predictive value of AF recurrence between LA dimension and PV/LA%vol in the tertile groups according to the LA dimension in selected patients who underwent circumferential PV isolation alone.

Comparisons of AUCs between PV/LA%vol and LA dimension in the T1 (A), T2 (B), and T3 (C) LA dimension groups.

AF, atrial fibrillation; AUC, Area under the receiver operating characteristic curve; CPVI, circumferential pulmonary vein isolation; LA, left atrium or left atrial; PV/LA%vol, pulmonary vein to left atrium volume percent ratio.

**Supplementary Table 1.** Cox regression analysis for clinical recurrence after AFCA in selected patients who underwent PV isolation alone.

	Univariate		Multivariate		
	HR (95% CI)	P	HR (95% CI)	P 0.001	
Persistent AF	1.42 (1.18–1.72)	< 0.001	1.52 (1.18–1.95)		
Female	1.27 (1.06–1.51)	0.009	0.009 1.49 (1.17–1.90)		
Age	1.00 (0.99–1.01)	0.837			
Body mass index	1.02 (0.99–1.04)	0.219			
Comorbidity					
Hypertension	1.15 (0.98–1.36)	0.088			
Diabetes	1.15 (0.92–1.44)	0.212			
Heart failure	1.33 (1.02–1.72)	0.033	1.28 (0.87–1.89)	0.206	
Vascular disease	0.75 (0.57–1.01)	0.054			
LV ejection fraction	0.99 (0.98–1.00)	0.029 1.00 (0.98–1.01		0.765	
E/Em	1.02 (1.00–1.04)	0.076			
Extra-PV foci	2.35 (1.74–3.17)	< 0.001	2.22 (1.64–3.00)	< 0.001	
PV/LA%vol	0.90 (0.84–0.97)	0.003	0.90 (0.82–1.00)	0.040	
Genetic study (n=1627)					
rs12646447 <sup>†</sup>	0.96 (0.79–1.16)	0.655			

<sup>&</sup>lt;sup>†</sup> Univariate analysis was performed in 1627 out of 2219 patients who had data on genetic study.

AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; CI, confidence interval; E/Em, ratio of the peak mitral flow velocity of the early rapid filling to the early diastolic velocity of the mitral annulus; LA, left atrium; LV, left ventricular; PV, pulmonary vein; PV/LA%vol, pulmonary vein to left atrium volume percent ratio.

**Supplementary Table 2.** Associated SNPs in *PITX2* with PV/LA%vol in two different cohorts.

Chr	SNP	Position	Closest gene		Cohort 1			Cohort 2	
				(n=1020)			(n=1131)		
				β	95% CI	P	β	95% CI	P
4	rs12646447	110778170	PITX2	0.12	0.02-0.23	0.020	0.17	0-0.33	0.045
4	rs10019689	110728713	PITX2	0.12	0.02-0.22	0.017	NA	NA	NA
4	rs17042171	110787131	PITX2	0.12	0.02-0.23	0.020	NA	NA	NA
4	rs2200733	110789013	PITX2	0.12	0.02-0.22	0.022	NA	NA	NA
4	rs72672233	111070319	PITX2	0.11	0-0.23	0.048	NA	NA	NA
4	rs297014	111082215	PITX2	-0.11	-0.20.02	0.022	NA	NA	NA
4	rs145701953	111416401	PITX2	-0.32	-0.64-0	0.048	NA	NA	NA
4	rs13131353	112878619	PITX2	-0.15	-0.200.02	0.020	NA	NA	NA
4	rs10033464	110799605	PITX2	NA	NA	NA	0.22	0.01-0.43	0.041
4	rs13130446	110818000	PITX2	NA	NA	NA	0.24	0.08-0.39	0.003
4	rs11098092	110877045	PITX2	NA	NA	NA	0.18	0.03-0.34	0.020

NA, not available; PV/LA%vol, pulmonary vein to left atrium volume percent ratio; SNP, single nucleotide polymorphism.